Evidence map›Paper›PMID 34940418›Full record

ReviewMembranes2021

Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids.

Manuel Torres, Sebastià Parets, Javier Fernández-Díaz, Roberto Beteta-Göbel, Raquel Rodríguez-Lorca, Ramón Román, Victoria Lladó, Catalina A Rosselló, Paula Fernández-García, Pablo V Escribá

Open access · goldAbstract readReview
In one paragraph

Review in Membranes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Monocaprin, Monolaurin, and Monomyristin EradicatePharmaceuticals (Basel, Switzerland) · 2026
    Article
  7. Review
  8. Review
  9. Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma.International journal of molecular sciences · 2026
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Manuel TorresLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.ORCID 0000-0002-5076-8486
Sebastià ParetsLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
Javier Fernández-DíazLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
Roberto Beteta-GöbelLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.ORCID 0000-0002-4651-8433
Raquel Rodríguez-LorcaLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
Ramón RománLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
Victoria LladóLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
Catalina A RossellóLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.ORCID 0000-0002-8977-607X
Paula Fernández-GarcíaLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.ORCID 0000-0002-8128-7028
Pablo V EscribáLaboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.ORCID 0000-0001-9795-182X
Universitat de les Illes Balears · ES

Funding

European Commission 755179Govern de les Illes Balears ES01/TCAI/21_2017Govern de les Illes Balears ES01/TCAI/24_2018Govern de les Illes Balears ES01/TCAI/53_2016Govern de les Illes Balears FPI/1981/2016Govern de les Illes Balears FPI/2063/2017Govern de les Illes Balears PD/058/2020Govern de les Illes Balears PROCOE/5/2017Ministerio de Ciencia e Innovación PID2020-115602RA-I00Ministerio de Ciencia e Innovación RTC2019-007399-1Ministerio de Economía y Competitividad BES-2014-067883Ministerio de Economía y Competitividad DI-14-06701Ministerio de Economía y Competitividad PTQ-17-09056
6 · The paper itself

Abstract

Membranes are mainly composed of a lipid bilayer and proteins, constituting a checkpoint for the entry and passage of signals and other molecules. Their composition can be modulated by diet, pathophysiological processes, and nutritional/pharmaceutical interventions. In addition to their use as an energy source, lipids have important structural and functional roles, e.g., fatty acyl moieties in phospholipids have distinct impacts on human health depending on their saturation, carbon length, and isometry. These and other membrane lipids have quite specific effects on the lipid bilayer structure, which regulates the interaction with signaling proteins. Alterations to lipids have been associated with important diseases, and, consequently, normalization of these alterations or regulatory interventions that control membrane lipid composition have therapeutic potential. This approach, termed membrane lipid therapy or membrane lipid replacement, has emerged as a novel technology platform for nutraceutical interventions and drug discovery. Several clinical trials and therapeutic products have validated this technology based on the understanding of membrane structure and function. The present review analyzes the molecular basis of this innovative approach, describing how membrane lipid composition and structure affects protein-lipid interactions, cell signaling, disease, and therapy (e.g., fatigue and cardiovascular, neurodegenerative, tumor, infectious diseases).

Indexed as

infectious pathologieslipid replacementlipidslipid switchesmelitherapyneurodegenerationoncologypathophysiologytherapy

Identifiers

PMID34940418
PMCPMC8708953
OpenAlexW3214827622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.